Literature DB >> 19868420

STUDIES ON EXPERIMENTAL PNEUMONIA : V. ACTIVE IMMUNITY AGAINST EXPERIMENTAL PNEUMOCOCCUS PNEUMONIA IN MONKEYS FOLLOWING VACCINATION WITH LIVING CULTURES OF PNEUMOCOCCUS.

R L Cecil1, F G Blake.   

Abstract

1. The subcutaneous injection of small doses of living virulent Pneumococcus Type I stimulates in monkeys a degree of active immunity sufficient to protect them against experimental pneumococcus pneumonia of homologous type. 2. The subcutaneous injection of living avirulent Pneumococcus Type I, if administered in a sufficiently large dose, likewise renders the monkey immune to a subsequent pneumonia of homologous type. 3. Vaccination of monkeys with small doses of living virulent pneumococci may or may not be followed by a severe constitutional reaction, depending on the natural resistance of the individual. The severe reactions are caused by the development of a pneumococcus septicemia. which is either temporary, or leads to a fatal termination. The mild reactions are not accompanied by septicemia, and there are no symptoms other than a slight elevation of temperature and moderate leucocytosis. Vaccination with living avirulent pneumococci does not induce severe reactions and is not accompanied by pneumococcus septicemia. 4. Active immunity against pneumococcus pneumonia, produced by vaccination with living pneumococci, appears to be largely independent of the presence or absence of agglutinins and protective bodies in the serum of the monkey. 5. Vaccination with living cultures of Pneumococcus Type I confers against other types of pneumococci a certain amount of cross-immunity which, however, varies considerably with the individual monkey. 6. immunity against pneumococcus, like other forms of immunity, is a relative term, and depends upon the capacity of the individual for antibody production, the virulence of the invading microorganism, and the size of the dose injected.

Entities:  

Year:  1920        PMID: 19868420      PMCID: PMC2128249          DOI: 10.1084/jem.31.6.657

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  3 in total

1.  STUDIES ON EXPERIMENTAL PNEUMONIA : I. PRODUCTION OF PNEUMOCOCCUS LOBAR PNEUMONIA IN MONKEYS.

Authors:  F G Blake; R L Cecil
Journal:  J Exp Med       Date:  1920-03-31       Impact factor: 14.307

2.  STUDIES ON EXPERIMENTAL PNEUMONIA : IV. RESULTS OF PROPHYLACTIC VACCINATION AGAINST PNEUMOCOCCUS PNEUMONIA IN MONKEYS.

Authors:  R L Cecil; F G Blake
Journal:  J Exp Med       Date:  1920-04-30       Impact factor: 14.307

3.  STUDIES ON EXPERIMENTAL PNEUMONIA : III. SPONTANEOUS PNEUMONIA IN MONKEYS.

Authors:  F G Blake; R L Cecil
Journal:  J Exp Med       Date:  1920-04-30       Impact factor: 14.307

  3 in total
  6 in total

1.  The pneumococcus and some men who came to Yale: the Dorothy M. Horstmann Lecture.

Authors:  R Austrian
Journal:  Yale J Biol Med       Date:  1993 Jul-Aug

2.  ACTIVE AND PASSIVE IMMUNITY TO PNEUMOCOCCUS INFECTION INDUCED IN RABBITS BY IMMUNIZATION WITH R PNEUMOCOCCI.

Authors:  W S Tillett
Journal:  J Exp Med       Date:  1928-11-30       Impact factor: 14.307

3.  THE EFFECT OF INCREASED ANTIPNEUMOCOCCAL IMMUNITY ON THE INCEPTION OF EXPERIMENTAL LOBAR PNEUMONIA IN THE DOG.

Authors:  O H Robertson
Journal:  J Exp Med       Date:  1937-11-30       Impact factor: 14.307

4.  EXPERIMENTAL PNEUMONIA IN GUINEA PIGS : II. EFFECT OF ANTI-AUTOLYSATE SERA ON PNEUMOCOCCUS PNEUMONIA IN GUINEA PIGS.

Authors:  J T Parker
Journal:  J Exp Med       Date:  1929-07-31       Impact factor: 14.307

5.  STUDIES ON EXPERIMENTAL PNEUMONIA : VII. TREATMENT OF EXPERIMENTAL PNEUMOCOCCUS TYPE I PNEUMONIA IN MONKEYS WITH TYPE I ANTIPNEUMOCOCCUS SERUM.

Authors:  R L Cecil; F G Blake
Journal:  J Exp Med       Date:  1920-06-30       Impact factor: 14.307

6.  REACTIONS OF RABBITS TO INTRACUTANEOUS INJECTIONS OF PNEUMOCOCCI AND THEIR PRODUCTS : VII. THE RELATION OF HYPERSENSITIVENESS TO LESIONS IN THE LUNGS OF RABBITS INFECTED WITH PNEUMOCOCCI.

Authors:  L A Julianelle; C P Rhoads
Journal:  J Exp Med       Date:  1932-04-30       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.